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ABSTRACT  
The present study was carried out to evaluate the acute and sub-acute toxicity of Algerian Peganum harmala L. seeds (Zygophyllaceae). For the 
acute toxicity assessment, oral administration of P. harmala crud extract to mice in single doses of 0-12 g/kg caused dose-dependent general 
behavior adverse effects and mortality with LD50 of 2,86 g/kg. In the sub-acute study, daily oral administration of the crude aqueous extract for 
28 consecutive days did not result no mortality. However, our results showed a significant difference in organs weights between control and 
treated animals. In the biochemical analysis, significant changes occurred in Bilirubin, uric acid (UA) and alkaline phospha tase (ALP) in the 
treated animals when compared to the control ones. Hematological analysis showed differences in WBC count and Hemoglobin esti mation. 
However, urinalysis was negative for all parameters except Glucose in the treated group. Pathologically, a few gross abnormalities and 
histological changes were observed in hepatic and nephritic tissues. 
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Medicinal plants are believed to be an important source of 
chemical substances with potential therapeutic effects. Thus, 
studying of traditional medicinal plants used as pain killers 
should be sees as a logical strategy in search for new drugs. 
Peganum harmala L. (Zygophyllaceae), commonly known in 
Algeria as Harmel, is one of Algerian medicinal plants that 
grow in semi-arid conditions, steppe areas and sandy soils 
[1]. It is mainly found in eastern Mediterranean region, 
Central Asia, North Africa and Middle East [2]. In folk 
medicine, the seeds are known to possess abortive, 
emmenagogue, narcotic, anti-spasmodic, anti-asthmatic, 
anti-rheumatism and anti-cancer properties [3].  There are 
several reports in the literature indicating a great variety of 
pharmacological activity for P. harmala L. extracts: analgesic 
[4], anti-nociceptive [5], hypoglycemic [6], vasorelaxant [7], 
antioxidant [8], anti-microbial [9], anti-helminthic [2], anti-
HSV [10], and cytotoxic properties [1]. 
However, all parts of this plant, especially seeds, are thought 
to be toxic and sever intoxication symptoms like 
hypothermia, vomiting, respiratory troubles, hallucination 
and convulsions were occurred in domestic animals and few 
human cases [11, 12].  
Many studies reported that a wide spectrum of beneficial and 
toxicological effects of P. harmala is attributed to the 
presence of many bioactive compounds: fixed oils [13, 14] 
saponins [15], polyphenols [8] and alkaloids which are the 
major compound with up of 10% of the total seeds dry 
weight. These alkaloids are mainly comprised of β-carboline 
and quinazoline derivatives, including Harman, Harmine, 
Harmaline [16], Peganine and Desoxypeganine [17, 18]. The 
β-carboliniques alkaloids have neuro-pharmacological and 
toxicological effects such as: deactivation of Monoamine 
Oxidase type A (MAO-A), inhibition of the recapture of 
serotonin and agonist of serotonin and dopamine receptors 
[19, 20 and 21]. Furthermore, the studies of Tuliaganov et al. 
[22] showed that quinazoline alkaloids were inhibitors of the 
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acetyl-cholinesterase (AChE): the responsible enzyme in the 
degradation of acetylcholine.  
In the present study, we evaluate the toxicological effects to 
define the safe dose of the seeds of P. harmala and protect 
the users from their possible toxic effects. Furthermore, this 
is the first time P. harmala crud extract has been studied in 
short-term oral administration for hepatic and 
nephrotoxicity on the biochemical and histological levels in 
mice. 
MATERIALS AND METHODS 
Plant material  
Peganum harmala seeds were purchased from a local herbal 
medicine store of Wilaya of Mila – Algeria in September 
2012. The plant was authenticated by Pr. Laouar H. - 
Department of Vegetal biology - Faculty of Natural and Life 
Sciences - University Ferhat Abbas - Sétif, Algeria.  
Experimental animals  
Male and female Albino Swiss mice (3 months old, weighting 
29.21 ± 2.79 g) were obtained from Pasteur Institute 
(Algiers, Algeria). These animals were kept in an air-
conditioned animal room at the animal house of the Nature 
and Life Sciences Faculty - University of Sétif with natural 
photoperiod cycle. The animals were housed in plastic cages 
(5 animals per cage with separation of both sexes) and had 
free access to standard commercial diet and tap water. 
Preparation of P. harmala extract 
The seeds of P. harmala were cleaned, air-dried and ground 
to a powder using a manual grinder. Crud extract was 
prepared by adding 100 g of seed powder to 1 liter of 
methanol/distilled water mixture (80/20) for 24 hours and 
the resulting macerate was filtered using Wattman paper 
n°3. These steps were repeated another time. The resulting 
filtrate was evaporated in rotary vacuum evaporator at 45 °C 
to get the crud extract (CE). 
 Acute toxicity study of the Crud extract (CE) 
In this study, CE was administered orally using 7 groups of 
mice (10 mice of both sexes in each group) at singles doses of 
0, 0.1, 0.5, 1, 3, 6 and 12 g/kg of body weight. The behavioral 
changes and signs of toxicity and/or mortality of mice was 
monitored directly after dosing, periodically during the first 
24 hours (with special attention given during the first 6 
hours), then daily for a total period of 14 days [23]. Lethal 
dose value (LD50) was determined using Miller and Trainer 
method (1944) according to Randhawa [24]. 
Sub-acute toxicity study of CE 
Female mice were divided into two groups of 8 mice each; 
treated and control group. The treated group received CE 
daily by gavage at dose of 285.8 mg/kg/day for 28 
consecutive days. Whereas, control group received only the 
distilled water during the treatment period. Toxic 
manifestations and mortality were monitored daily, and the 
body weight changes were recorded every day [25].  
Organ’s weight  
After blood collection, animals were euthanized with diethyl 
ether and their vital organs such as liver, kidneys, heart, 
lungs, spleen, brain and stomach were carefully dissected 
out, rinsed with 0.9% NaCl solution and weighed individually 
(absolute organ weight). 
Blood analysis 
At the end of the 28-day period, animals were anesthetized 
slightly by diethyl ether and blood was collected by cardiac 
puncture in two tubes: one with ethylene di-amine tetra-
acetate (EDTA) and the other with heparin. EDTA tube was 
processed immediately for hematological parameters 
analysis and the heparinized blood was centrifuged at 4000 
rpm at 4 C° for 10 min to obtain serum (stored at −20 °C until 
biochemical analysis).  
Analysis of hematological parameters including: red blood 
cell (RBC), white blood cell (WBC), hemoglobin, hematocrit, 
mean corpuscular hemoglobin concentration (MCHC), mean 
corpuscular volume (VGM), platelets and mean platelet 
volume (MPV), was performed using automatic 
hematological analyzer (Beckman Coulter® - AcT diff 2). For 
biochemical analysis, the serum was analyzed for cholesterol 
(CHOL), glucose, creatinine, aspartate aminotransferase 
(AST), alanine aminotransferase (ALT), triglycerides (TG), 
uric acid (UA), alkaline phosphatase (ALP), bilirubin and 
total Proteins (TP). Dosages were made using automatic 
analyzer (Beckman Coulter® AU680). 
Urine simples 
Urine samples (0.5–1.5 ml) were collected during 2–4 hours 
for each animal in a metabolic cage. Urinalysis was 
undertaken using urine test strip Siemens® (Multistix 8 SG). 
Liver and kidney tissues histopathological examination  
Fresh rinsed liver and kidney tissues of all animals were 
fixed in buffered formaldehyde solution (10 %), dehydrated 
by serial ethanol solution (70-90 %), cleared in xylene and 
enclosed with paraffin. Five micrometers sections, cut by a 
microtome (Carl Zeiss® Jena), were stained with 
hematoxylin-eosin [26] and examined under a light 
microscope; photomicrographs of the samples were 
recorded. 
Statistical analysis 
All results are expressed as the mean value ± standard 
deviation. The Student’s t-test was used to assess the 
differences between data. Differences were considered 
significant at p < 0.05. Statistical analyses were performed 
with GraphPad Prism 5®. 
RESULTS 
Acute toxicity 
The results of the toxicity study of CE given orally as single 
doses are presented in Table 1. The adverse effects and 
lethality increased progressively with increasing oral doses 
from 0.1 to 12 g/kg. Some adverse effects, such as hypo-
activity, piloerection, trembling, breathing difficulty, 
bradycardia, diffuse tremors and convulsions were observed 
immediately after administration. They were more 
pronounced at higher doses (3, 6 and 12 g/kg) and persisted 
until death. Toxic effects, mortality and latency appeared to 
be gender-depending where the males being more sensitive 
than females. The acute toxicity data indicated that the 
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Permanente hypo-activity, piloerection, anorexia, bradycardia, trembling, 
breathing difficulties, dyspnea and convulsions. 







Permanente hypo-activity, piloerection, anorexia, bradycardia, trembling, 
breathing difficulties, dyspnea, convulsions, loss of balance, muscular spasms, 
narcosis with occasional periods of excitations leading to the death. 





Permanente hypo-activity, piloerection, anorexia, bradycardia, trembling, 
breathing difficulties, dyspnea, convulsions,  loss of balance, muscular spasms, 
narcosis with occasional periods of excitations leading to the death. 
10mn - 
27h 
F : female ; M : male ; T : total ; D : death ; h : hour ; mn : minute 
 
Sub-acute toxicity studies 
Clinical observations and body weight  
Daily oral administration of CE for 28 consecutive days did 
not produce any obvious symptoms of toxicity or mortality 
(Table 2). Compared to the baseline value, no significant 
change was observed in body weight between treated and 
control animals, except a slight weight gain in the week 4.
 
Table 2. Effect of sub-acute oral administration of CE on body weight. 
WEEKS Control Treated 
Body weight (g) Weight gain (%) Body weight (g) Weight gain (%) 
W 1 33.58 ± 1.36 0.83 ± 0.2 32.12 ± 2.47 ns  0.63 ± 1.11 ns 
W 2 35.32 ± 1.15 1.73 ± 0.87 32.67 ± 2.95 ns 0.55 ± 1.79 ns 
W 3 34.53 ± 0.84 0.95 ± 0.79 32.26 ± 3.14 ns 0.14 ± 1.83 ns 
W 4 36.31 ± 1.46  2.73 ± 0.83 33.14 ± 3.41ns 1.01 ± 0.75 * 
Values are expressed as mean ± SD (n = 8/group). W1-W4: Weeks of the study. ns p > 0.05; * p<0.05 when compared to the 
control group (Student’s t-test). 
 
Effect of CE on hematological and biochemical 
parameters 
The values for the hematological and biochemical 
parameters in treated and control animals are presented in 
Table 3 and 4, respectively. Oral administration of CE for 28 
consecutive days did cause anemia with a low significant 
decrease of 23 % and 12 % in RBC and Hemoglobin, 
respectively (P<0.05). However, a significant increase of 144 
% (P<0.01) in WBC was noticed in the blood of treated 
animals when compared to the control ones. Similarly to the 
hematological analysis, a high significant change was 
observed in the level of UA, followed by a significant change 
in ALP and Bilirubin levels. On the other hand, the sub-acute 
treatment with 285.8 mg/kg did not show any significant 
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Table 3. Effect of sub-acute oral administration of CE on biochemical parameters in treated and control animals after 28 days. 
Parameter Control Treated 
Glucose (g/L)  1,34 ± 0,31 1,28 ± 0,11 ns 
ALAT (UI/L) 23,33 ± 6,66 27,2 ± 3,83 ns 
ASAT (UI/L) 152,33 ± 18,77 168 ± 28,87 ns 
ALP (UI/L) 42,7 ± 6,67 74,4 ± 8,17 ** 
Creatinin (mg/L) 4,33 ± 0,57 4,5 ± 1 ns 
UA (mg/L) 12 ± 3,46 42,8 ± 6,83 *** 
TP (g/L)  70,15 ± 6,83 70,12 ± 6,97 ns 
Bilirubin (mg/L) 1 ± 0,40 1,4 ± 0,2 * 
TG (g/L) 1,07 ± 0,46 0,65 ± 0,10 ns 
Cholesterol (g/L) 1,08 ± 0,37 1,04 ± 0,22 ns 
Values are expressed as mean ± SD (n = 8/group). *** p< 0.001; ** p< 0.01 ; * p< 0.05 ; ns p> 0.05 compared to the control group (Student’s t-
test ). ALAT: alanine amino-transferase, ASAT: aspartate amino-transferase, ALP: alkaline phosphatase, UA: uric acid, TP: total proteins, TG: 
triglycerides. 
 
Table 4. Effect of sub-acute oral administration of CE on hematological parameters in treated and control animals after 28 days. 
Parameters Control  Treated  
RBC (106/mm3) 9,51 ± 1,17 6,95 ± 1,34 * 
WBC (103/mm3) 3,15 ± 0,49 7,7 ± 0,98 ** 
Platelets (103/mm3) 1513,5 ± 516,89 1110,8 ± 161,19 ns 
Hematocrit (%) 44,35 ± 2,19 37,33 ± 8,43 ns 
Hemoglobin (g/dL) 14,35 ± 0,35 12,5 ± 0,7 * 
MCHC (g/dL) 30,75 ± 1,88 31,3 ± 2,21 ns 
MGV (µm3) 56,86 ± 9,61 49,96 ± 3,04 ns 
MPV (µm3) 4,96 ± 0,43 5,07 ± 0,40 ns 
Values are expressed as mean ± SD (n = 8/group). * p<0.05; ** p<0.01; 
ns 
p> 0.05, compared to the control group (Student’s t-test). RBC: red 




The urinalysis of urine parameters such as specific gravity, 
pH, glucose, protein, urea acid, ketone, leukocytes and occult 
blood, did not reveal any changes following sub-acute 
administration except a significant change on glucose levels 
in the treated animals when compared to the control ones 
(Table 5). 
Effect of CE on organ’s relative weight 
Absolute and relative organ weights of the control and 
treated animals are shown in Table 6. There was no 
modification in organs weight except a slight significant 
change on kidneys relative weight of the treated animals 
compared to the control ones. 
Table 5. Effect of sub-acute oral administration of CE on 
urine parameters. 
Parameter Control Treated 
Glucose (g/dL) Negative 100 ± 0.0 
 
Table 6. Effect of sub-acute oral administration of the CE on relative organ’s weight in animals after 28 days. 
Organ Control  Treated  
 Organ weight Relative organ weight Organ weight Relative organ weight 
Liver  1.66 ± 0.17 5.33 ± 0.64 1.48 ± 0.22 5.13 ± 0.49 ns 
Kidneys 0.38 ± 0.03 1.21 ± 0.14 0.40 ± 0.06 1.39 ± 0.11* 
Heart  0.15 ± 0.00 0.5 ± 0.04 0.15 ± 0.02 0.53 ± 0.06 ns 
Stomach  0.35 ± 0.07 1.14 ± 0.28 0.31 ± 0.05 1.09 ± 0.15 ns 
Spleen  0.19 ± 0.02 0.62 ± 0.07 0.17 ± 0.05 0.59 ± 0.12 ns 
Lungs  0.24 ± 0.03 0.78 ± 0.08 0.24 ± 0.02 0.82 ± 0.08 ns 
Brain 0.46 ± 0.04 1.48 ± 0.15 0.44 ± 0.07 1.52 ± 0.23 ns 
Values are expressed as mean ± SD (n = 8/group). * p < 0.01 ; 
ns 
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Effect of CE on histological morphology of liver and 
kidney 
Histological examination of the liver and kidney has clearly 
shown that the cellular and tissular architecture (lobular 
and tubular) of both organs is well preserved in both control 
and treated animals. However, some features were 
considered. Microscopic observation showed a normal liver 
histological morphology in control group. However, a 
discrete vascular and sinusoidal congestion, dilated 
sinusoids and tissue lesion were observed in the liver tissue 
of some treated animals (Figure 1). Furthermore, sub-acute 
administration of CE extract revealed the presence of a 
major vascular congestion, inflammatory infiltrate and 
cytolysis in some treated animals (Figure 2). 
 
                 
Figure 1. Effects of CE on histological morphology of the liver.  A) Control group. B) Treated group.  CLV: Centro lobular vein; 
SE : sinusoid etroit; H : hepatocyte ; L : tissular  lesion; SD : sinusoidal  dilatation; SC : sinusoidal congestion. 
 
                   
Figure 2. Effects of CE on histological morphology of the kidney. A) Control group. B) Treated group. G : glomeruli ; T : tubule ; 
VC : vascular congestion; IF : inflammatory infiltrate. 
 
DISCUSSION 
As we reported above, P. harmala could possess a variety of 
physiological and pharmacological properties. However, a 
toxicological evaluation needs to be performed to define the 
safety of P. harmala and to protect the users from their 
possible toxic effects.  
Toxicologists usually divide the chemical toxicity into 3 
categories: acute, sub-acute and chronic toxicity. Acute 
toxicity is defined as the exposure of animals to a chemical 
for less than 24 hours. Sub-acute toxicity refers to repeated 
exposure to a chemical for 1 month or less and chronic for 
more than 3 months [27]. In the present study, the period of 
exposure was less than 24 h and 28 days, so in this study we 
used an acute and a sub-acute model, respectively. 
In the present study, male and female Albino Swiss mice 
were orally administered CE of P. harmala at single doses of 
0, 0.1, 0.5, 1, 3, 6 and 12 g/kg of body weight in acute toxicity 
study and daily at a dose of 285.8 mg/kg of body weight for 
28 consecutive days for sub-acute toxicity study. Throughout 
14 days of acute study, CE produced toxicity and mortality in 
mice and LD50 was equal to 2.86 ± 1.17 g/kg. According to 
the classification of Hodge and Sterner [28], chemical 
substance with a DL50 between 500 and 5000 mg/kg is 
considered practically as lightly toxic in humans. Hence, the 
CE could be considered as a lightly toxic compound. 
Considering the crud extract yield (20.18 %), it appears that 
LD50 of CE of P. harmala was 14.16 g of dry seed /kg of body 
weight that gives a good safety marge of the use of this plant 
in traditional medicine. Similar results have been reported in 
other studies: Lamchouri et al. [29] found that LD50 of the 
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aqueous extract of P. harmala seeds administered orally in 
rats was 2.7 g/kg. On the other hand, the sub-acute toxicity 
study in female mice receiving CE orally at the dose of 285.8 
mg/kg during 28 days did not show any signs of intoxication 
or mortality during the treatment period.  
The hematopoietic system is one of the most sensitive 
targets for toxic compounds, and an important index of 
physiological and pathological status in human and animals 
[30, 31]. Changes in hematological and biochemical system 
have a higher value for human toxicity, when the data are 
translated from animal models [32, 33]. Sub-acute exposure 
of mice of the CE produced a clear modification in some 
hematological and biochemical parameters which 
accompanied with significant alteration of the liver and 
kidney morphology (see later).  
Our results showed that CE has produced a decrease in RBC 
and HB and an increase in WBC. Differently, Muhi-eldeen et 
al. [34] did not show any hematological perturbations 
during 6 weeks of intramuscular administration of P. 
harmala alkaloids extract in rats. The decrease in RBC and 
HB may be due to the anemia explicated by an 
erythropoiesis disorders, decrease of hemoglobin synthesis 
and/or RBC hemolysis [35]. Several reports have reported 
the in vitro hemolytic activity of saponins when they were 
mixed with a RBC suspension [36, 37]. Hence, any plant 
extracts contains saponins may be produce a sever 
hemolytic anemia [38]. In fact, El Allagui et al. [15] have 
already showed that P. harmala extracts comprise saponins 
which the composition and structure are not clearly 
investigated. Furthermore, the increase of WBC in treated 
mice refers to reinforcement of the immune system [35]. 
This suggests that CE contains powerful bioactives 
substances amplifying the immune system and increasing 
the rate of WBC: the first defensive level in the organism 
[39]. 
Photomicrographs of the sections of the liver and kidney of 
mice treated orally with the dose of 285.8 mg/kg for 28 days 
show a discrete vascular and sinusoidal congestion, dilated 
sinusoids and tissue lesion in the live, and marked vascular 
congestion, inflammatory infiltration and cytolysis in the 
kidney. The hepatotoxicity of CE is also supported by a 
marked elevation of alkaline phosphatase (ALP) and 
Bilirubin with normal levels of transaminases. A different 
result was reported by Lamchouri et al. [29]: they found that 
chronic exposure to P. harmala alkaloids extracts increased 
significantly the levels of transaminases (ASAT and ALAT) in 
rats. This difference may be referred to the treatment period 
(sub-acute and chronic) or the administered dose (258.8 
mg/kg and 2000 mg/kg). According to Wallace and Meyer, 
[40], ALP is good indicator of liver function and predicting 
possible toxicity as well as transaminases (ASAT and ALAT). 
Generally, ASAT and ALAT found in the serum are of both 
mitochondrial and cytoplasmic origin. However, ALP is a 
ubiquitous enzyme particularly in the liver biliary tract, 
kidney, bones and placenta, where it is highly concentrated. 
Thus, any significant increase in ALP levels in serum may be 
due to the presence of an obstruction of the intrahepatic bile 
ducts, primary biliary cirrhosis or disruption of the liver 
architecture [41]. Similarly, Bilirubin (a breakdown product 
of hemoglobin) may be another indicator in the assessment 
of liver function. Hyper-bilirubin level indicated the 
presence of an obstruction of the intrahepatic bile ducts, 
disruption of the liver architecture or hemolytic anemia [39, 
42]. Thus, the results recorded in this study suggest that CE 
altered the liver and biliary tracts architectures and 
functions. Differently, the results of biochemical examination 
for nephric parameters could not explain the marked 
histological changes of the kidney. The sub-acute treatment 
with CE did not induce any significant change in creatinine 
level: the major biological marker of renal dysfunction [43]. 
However, a significant increase in uric acid in serum was 
noted which can be explained by the elevation of the protein 
degradation [44]. 
Liver is the site of cholesterol disposal or degradation and its 
major site of synthesis. In the same perspective, the liver 
controls glucose synthesis and generates free glucose from 
hepatic glycogen stores. As no significant changes were 
observed in glucose and cholesterol levels in this study, this 
suggests that CE had no effects on the lipid and carbohydrate 
metabolism of the mice. The other biochemical parameters 
such as TP and TG showed no significant changes between 
treated and control groups. 
A wide spectrum of beneficial and toxicological effects of P. 
harmala is attributed to the presence of many bioactive 
compounds especially alkaloids. These alkaloids are mainly 
comprised of β-carboline and quinazoline derivatives [16, 
17, and 18]. They have neuro-pharmacological and 
toxicological properties such as inhibition of MAO-A [19, 20 
and 21] and AChE [22]. All together, these neuro-
pharmacological properties may be used to explain mortality 
and signs of intoxication during the acute toxicity study with 
higher doses of CE. In addition, β-carboliniques alkaloids 
may have not only neurotic actions but also cytotoxic ones. 
Nafisi et al. [1] and Sobhani et al. [45] proved that can β-
carboliniques alkaloids could intercalate between 
nitrogenous bases of the DNA leading to the inhibition of 
DNA topoisomerase I, and therefore, the inhibition of DNA 
replication and cell division. 
CONCLUSION 
In conclusion, we showed that P. harmala could be lightly 
toxic according to the consumed doses in Algerian folk 
medicine. However, at higher doses and for long time 
exposure, the seeds extracts can cause several hepatic and 
nephritic toxicities. 
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